Clinical Trials Sponsored by Mitsubishi Tanabe Pharma America Inc.

Total 274 results

Mitsubishi Tanabe Pharma America Inc.

Terminated

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

ALS

United States, Canada, Japan, Germany, Korea, Republic of, Switzerland
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

Spinal Cord Injury

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Menopause Hot Flashes

United States
Mitsubishi Tanabe Pharma America Inc.

Terminated

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Active, not recruiting

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

EPP | XLP

United States, Germany, Japan, Spain, Italy, Sweden, Australia, Canada, Norway, United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis

Spain, Belgium, United States, United Kingdom, Poland, Canada, Germany, Italy
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States, Canada, Japan, France, Germany, Italy
Mitsubishi Tanabe Pharma America Inc.

Completed

Mass Balance Study With MT-7117 (MT-7117 MB)

Healthy Volunteer

United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

Vasomotor Symptoms (VMS)

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

EPP | XLP

Spain, United States, Germany, Norway, Italy, Australia, Canada, Japan, Sweden, United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Mass Balance Study With MT-8554 (MT-8554 MB)

Healthy Volunteer

United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
Mitsubishi Tanabe Pharma America Inc.

Recruiting

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP (INSPIRE)

Erythropoietic Protoporphyria (EPP) | X-Linked Protoporphyria (XLP)

United States, Spain, France, United Kingdom, Japan, Italy, Australia, Bulgaria, Czechia, Netherlands, Poland
Mitsubishi Tanabe Pharma America Inc.

Recruiting

Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

Spinal Cord Injury

United States, Canada, Japan
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Erythropoietic Protoporphyria (EPP)

United States
Mitsubishi Tanabe Pharma America Inc.

Terminated

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

ALS

United States, Korea, Republic of, Canada, Germany, Japan, Italy, Switzerland
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety and Efficacy Study of MT-2990 in Women With Endometriosis

Endometrial Related Pain

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects

Healthy Subjects

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety Study of Oral Edaravone Administered in Subjects With ALS

ALS

United States, Canada, Japan, France, Germany, Italy
Mitsubishi Tanabe Pharma America Inc.

Completed

Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor (MT-7117 BA DDI)

Healthy Volunteer

Germany
Mitsubishi Tanabe Pharma America Inc.

Completed

Definitive QT Study With MT-8554 (MT-8554 DQT)

Healthy Volunteer

United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Healthy Subjects

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Renal Impairment | Normal Renal Function

Germany
Mitsubishi Tanabe Pharma America

Completed

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment

Healthy | Hepatic Impairment

Japan
Mitsubishi Tanabe Pharma America

Completed

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment

Healthy | Renal Impairment

Japan
Mitsubishi Tanabe Pharma America Inc.
Massachusetts General Hospital

Active, not recruiting

Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Amyotrophic Lateral Sclerosis | ALS

United States, Canada
Mitsubishi Tanabe Pharma Corporation

Recruiting

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Diffuse Large B-Cell Lymphoma

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)

HTLV-1-Associated Myelopathy (HAM)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy

Japanese Patients With ALS

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Non-dialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males

Healthy Adult Males

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia

Schizophrenia

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Study of MP-214 in Patients With Schizophrenia

Schizophrenia

Taiwan, Korea, Republic of, Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

Schizophrenia

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis

Pediatric Ulcerative Colitis

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)

NASH

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants

Healthy

Australia, South Africa
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

Seasonal Allergic Rhinitis

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Terminated

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

Acute Ischemic Stroke

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients

Systemic Lupus Erythematosus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy Volunteers

Healthy

Netherlands
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)
Mitsubishi Tanabe Pharma Corporation

Completed

Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects

Chronic Kidney Disease | Hyperphosphatemia

United Kingdom

Clinical Trials Sponsored by Mitsubishi Tanabe Pharma America Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations